France Sets Precedent With Off-Label Avastin Move
This article was originally published in Scrip
Executive Summary
True to its word, the French health ministry has announced that Roche's anticancer Avastin (bevacizumab) will be reimbursed for the off-label treatment of wet AMD as of Sept. 1, 2015. In doing so, the ministry is setting a precedent by encouraging the use of a drug for an unapproved indication for purely financial reasons.
You may also be interested in...
Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD
Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.